Sponsor Pipeline

Hangzhou Polymed Biopharmaceuticals, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
1
Active Trials
1
Recruiting
2
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-24 NCT07137637
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia		 Recruitment opened
2026-07-24 NCT07137637
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia		 date change Primary completion moved earlier: 2027-09-14 -> 2027-06
Active Trials by Phase
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 1
NCT07137637 HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) Recruiting
Disease Areas
Leukemia (1) Acute Myeloid Leukemia (AML) (1)
Get alerts when Hangzhou Polymed Biopharmaceuticals, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free